4-溴-2-氟-N,N-二甲基苯甲酰胺 | 749927-80-8

• 物质功能分类: 有机原料 - 氨基化合物 - 酰胺类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-氟-N,N-二甲基苯甲酰胺
• 英文名称: 4-bromo-2-fluoro-N,N-dimethylbenzamide
• CAS: 749927-80-8
• 化学式: C₉H₉BrFNO
• mdl: MFCD09878360
• 分子量: 246.079
• InChiKey: MKVVUOADKLZUTE-UHFFFAOYSA-N

物化性质

• 沸点：
  327.3±32.0 °C(Predicted)
• 密度：
  1.490±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362,P403+P233,P501
• 危险性描述：
  H302,H312,H332
• 储存条件：
  存放于室温、密封且干燥的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromo-2-fluoro-N,N-dimethylbenzamide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-2-fluoro-N,N-dimethylbenzamide
CAS number: 749927-80-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9BrFNO
Molecular weight: 246.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-2-氟-N,N-二甲基苯甲酰胺 在 盐酸 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium periodate 、 四丁基溴化铵 、 potassium acetate 、 palladium diacetate 、 potassium carbonate 、 tricyclohexylphosphine tetrafluoroborate 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 水 为溶剂， 反应 3.0h， 生成 2-[(5S)-2-[4-(dimethylcarbamoyl)-3-fluorophenyl]-5H-chromeno[2,3-b]pyridin-5-yl]-2-methylpropanoic acid
  参考文献：
  名称：

  实用合成的功能化氮杂蒽酮衍生的非甾体糖皮质激素受体调节剂的开发。

  摘要：

  报道了一种有效的途径来制备两个官能化的2-芳基-5 H -chromeno [2,3- b ]吡啶（金刚烷类）。向水杨醛中添加锂化的2,6-二氯吡啶，然后环化是确定形成氮杂黄嘌呤核的关键工艺改进。2-氯-5-的进一步阐述ħ -chromeno [2,3- b ]吡啶-5-醇在5位被通过与市售的（（1-甲氧基-2-甲基丙-1-路易斯酸催化的偶联来完成烯-1-基）氧基）三甲基硅烷。使用部分经典拆分方法与制备型手性超临界流体色谱法（SFC）分离来分离所需的氮杂蒽吨羧酸的对映异构体，该杂合体是两种化合物的共同中间体1和2。Suzuki-Miyaura与适当取代的硼酸交叉偶联，然后与2-氨基-1,3,4-噻二唑缩合，可提供目标化合物的总收率约为10％。还讨论了使用稳定的无定形材料来支持功能性氮杂黄嘌呤1和2的临床比较。

  DOI：

  10.1021/acs.oprd.6b00035
• 作为产物：
  描述：

  二甲胺 在 N,N-二甲基甲酰胺 草酰氯 、 三乙胺 、 盐酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.67h， 以54%的产率得到4-溴-2-氟-N,N-二甲基苯甲酰胺
  参考文献：
  名称：

  WO2006/64251

  摘要：

  公开号：

文献信息

• Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
  申请人：Borchardt Allen

  公开号：US20050176701A1

  公开（公告）日：2005-08-11

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R 1 and R 2 , are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  这项发明涉及公式1的化合物，以及其药学上可接受的盐、溶剂化合物、前药和代谢物，其中W、Z、R1和R2如本文所定义。该发明还涉及通过给哺乳动物施用公式1的化合物来治疗丙型肝炎病毒的方法，以及用于治疗这类疾病的含有公式1化合物的药物组合物。该发明还涉及制备公式1化合物的方法。
• FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS
  申请人：Bai Hao

  公开号：US20080280875A1

  公开（公告）日：2008-11-13

  The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R 1 , R 1a , R 2 , R 3 , R 4 , L 2 , n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

  本发明涉及以下式(I)的化合物：或其药用可接受的盐或溶剂，其中：环A为(4-12)成员杂环基；环B是从以下组中选择的融合苯环之一：环A、环B、环C、R1、R1a、R2、R3、R4、L2、n、t、w和z如规范中所定义。本发明还涉及包括式(I)的化合物的药物组合物以及治疗通过调节葡萄糖激酶介导的疾病的方法，该方法包括向哺乳动物施用有效量的式(I)的化合物。
• [EN] HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS<br/>[FR] INHIBITEURS HAUTEMENT SÉLECTIFS DE C-MET UTILISÉS COMME AGENTS ANTICANCÉREUX
  申请人：CROWN BIOSCIENCE INC TAICANG

  公开号：WO2014032498A1

  公开（公告）日：2014-03-06

  Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

  本文披露了新型含氮、杂环、c-Met抑制剂化合物，其制备方法和配方。这些化合物可用作治疗剂，用于抑制、调节和控制c-Met激酶信号通路，并用于治疗受c-Met介导的主体细胞增殖紊乱或疾病。
• INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
  申请人：Borchardt Allen

  公开号：US20060189681A1

  公开（公告）日：2006-08-24

  The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R 1 and R 2 , are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  本发明涉及式1的化合物以及其药学上可接受的盐、溶剂合物、前药和代谢物，其中W、Z、R1和R2如本文所定义。本发明还涉及通过给哺乳动物投予式1的化合物来治疗丙型肝炎病毒的方法，以及包含式1的化合物的用于治疗此类疾病的制药组合物。本发明还涉及制备式1的化合物的方法。
• 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
  申请人：Andrews David

  公开号：US20090099160A1

  公开（公告）日：2009-04-16

  Compounds of the formula (I): wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  化合物的公式（I）：其中变量基团如定义中所述，并描述了药物可接受的盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为产生细胞周期抑制（抗细胞增殖）作用的药物，用于温血动物，如人。